Investigating how NRF2 signaling contributes to a specific type of kidney cancer
Official title: Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma
Funded at Dana-Farber Cancer Inst · NIH-10881882 · Data updated 2026-11-12
This study is looking at a tough type of kidney cancer called translocation renal cell carcinoma (tRCC) to find out how it grows and survives, with the hope of discovering new treatments that could help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $464,974 |
| NIH project number | 5R01CA279044-02 |
| Project ID | NIH-10881882 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with translocation renal cell carcinoma.
✕Less likely to help
Patients with other types of renal cell carcinoma or those without a diagnosis of kidney cancer may not benefit from this research.
What this research studies
This research focuses on translocation renal cell carcinoma (tRCC), a particularly aggressive form of kidney cancer that arises from a gene fusion involving a transcription factor. The study aims to understand the molecular mechanisms that activate NRF2 signaling in tRCC, which is crucial for the cancer's growth and survival. By identifying how this pathway is regulated differently in tRCC compared to other cancers, the researchers hope to discover new therapeutic targets. Patients may benefit from potential new treatments specifically designed to target the unique biology of their cancer.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for patients with translocation renal cell carcinoma.
How similar studies have gone: While NRF2 signaling has been studied in other cancers, this research explores a novel regulatory mechanism specific to translocation renal cell carcinoma, making it a unique approach.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Viswanathan, Srinivas Raghavan — Dana-Farber Cancer Inst
- Study coordinator: Viswanathan, Srinivas Raghavan
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.